Sunday, July 3, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

WHO experts suggest antiviral drug for patients with non-severe covid-19 at highest risk of hospitalization

by Medical Finance
in Coronavirus
Fire closes hospital and displaces staff as Colorado battles omicron
9
SHARES
101
VIEWS
Share on FacebookShare on Twitter

The antiviral drug molnupiravir is conditionally recommended for patients with non-severe covid-19 who are at highest risk of hospitalization, says a WHO Guideline Development Group of international experts in The BMJ today.

Patients who are at highest risk of hospitalization typically include those who are unvaccinated, older people, and those with weak immune systems or chronic diseases.

However, the panel says that young and healthy patients, including children, and pregnant and breastfeeding women should not be given the drug due to potential harms.

Molnupiravir is an antiviral medicine that works by stopping coronavirus from growing and spreading. Used as early as possible after infection, it can help prevent more severe symptoms developing.

Today’s recommendation is based on new data from six randomized controlled trials involving 4,796 patients. This is the largest dataset on this drug so far.

Moderate certainty evidence from these trials suggests that molnupiravir reduces the risk of hospital admission (43 fewer admissions per 1,000 patients at highest risk) and time to symptom resolution (average 3.4 fewer days), while low certainty evidence suggests a small effect on mortality (6 fewer deaths per 1,000 patients).

The panel describes mitigation strategies needed at the population level, including pharmacovigilance and antiviral resistance monitoring, given concerns about genotoxicity (damage to a cell’s genetic information causing mutations), emergence of resistance and new variants.

They make no recommendation for patients with severe or critical illness as there are no trial data on molnupiravir for this population.

And they acknowledge that cost and availability issues associated with molnupiravir may make access to low and middle income countries challenging and exacerbate health inequity.

In the same guideline update, the panel recommends a treatment combining two antibodies (casirivimab and imdevimab) to be used in people who are confirmed not to have the omicron variant, as new evidence demonstrates a lack of effectiveness against the omicron variant.

Today’s recommendations are part of a living guideline, developed by the World Health Organization with the methodological support of MAGIC Evidence Ecosystem Foundation, to provide trustworthy guidance on the management of covid-19 and help doctors make better decisions with their patients.

Living guidelines are useful in fast moving research areas like covid-19 because they allow researchers to update previously vetted and peer reviewed evidence summaries as new information becomes available.

Today’s guidance adds to previous recommendations for the use of Baricitinib, interleukin-6 receptor blockers and systemic corticosteroids for patients with severe or critical covid-19; for the use of sotrovimab for patients with non-severe covid-19 and against the use of convalescent plasma, ivermectin and hydroxychloroquine in patients with covid-19 regardless of disease severity.

The recommendation for remdesivir is undergoing review due to new trial data. Recommendations for fluvoxamine and nirmatrelvir/ritonavir are currently in preparation.

Source:

Journal reference:

Agarwal, A., et al. (2020) A living WHO guideline on drugs for covid-19. The BMJ. doi.org/10.1136/bmj.m3379.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Bats host the most virulent—but not the most dangerous—zoonotic viruses. Image Credit: shutter_o / Shutterstock.com

Bats carry some of the most virulent, but not the most dangerous zoonotic viruses

by Medical Finance
July 3, 2022
0

The current coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is considered a...

Lung abnormalities may remain detectable long after COVID-19 pneumonia

As US nears 1 million covid deaths, one hard-hit county grapples with unthinkable loss

by Medical Finance
July 3, 2022
0

Connie Houtz didn't think covid would be that bad. She'd seen many people in this rural hamlet in central Pennsylvania...

When teens blow off parents’ pleas to get vaccinated, the consequences can be deadly

Additional boosters recommended for certain individuals at higher risk of severe COVID-19 outcomes

by Medical Finance
July 3, 2022
0

Data continue to show the importance of vaccination and booster doses to protect individuals both from infection and severe outcomes...

Study: The Efficacy of Common Household Cleaning Agents for SARS-CoV-2 Infection Control. Image Credit: Alexander Raths / Shutterstock.com

How effective are household cleaning agents against SARS-CoV-2?

by Medical Finance
July 3, 2022
0

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of the coronavirus disease 2019 (COVID-19), belongs to the...

Study: Case of a pregnant woman with probable prolonged SARS-CoV-2 viral shedding 221 days after diagnosis. Image Credit: Myriam B / Shutterstock.com

The longest duration of SARS-CoV-2 positivity after initial diagnosis

by Medical Finance
July 3, 2022
0

A new Journal of Infection and Chemotherapy study describes an immunocompetent individual with prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) shedding...

Study: Screening of wild deer populations for exposure to SARS-CoV-2 in the United Kingdom, 2020-2021. Image Credit: Mark Cane / Shutterstock

No evidence of SARS-CoV-2 in the U.K.’s wild deer population

by Medical Finance
July 3, 2022
0

A new study accepted for publication in the journal Transboundary and Emerging Diseases assesses the potential exposure of U.K. deer to the severe acute...

Next Post
Researchers fabricate highly-sensitive SERS probes to detect the PD-L1 biomarker

Researchers fabricate highly-sensitive SERS probes to detect the PD-L1 biomarker

Novel compound found in mussels helps increase the durability of dental fillings

Novel compound found in mussels helps increase the durability of dental fillings

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Stress 620x480
    The stress of restaurant work is reaching a boiling point. Could a staff therapist help?
  • Study: PERMISSIVE OMICRON BREAKTHROUGH INFECTIONS IN INDIVIDUALS WITH BINDING OR NEUTRALIZING ANTIBODIES TO ANCESTRAL SARS-CoV-2. Image Credit: ffikretow/Shutterstock
    Impact of binding antibody titers and RBD-ACE2 interaction inhibition titers on Omicron breakthrough infections
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply